Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05399498 · ClinicalTrials.gov registry record · Phase 2
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT05399498 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 9 participants.
The verdict
NCT05399498, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05399498
The ClinicalTrials.gov registry entry for NCT05399498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT05399498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05399498 about?
NCT05399498 is a clinical study titled "Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder". The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
What is the current status of trial NCT05399498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2023-11-01. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT05399498?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05399498?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.